Prolactin has been reported to be present in cervical mucus at concentrations higher than those found in blood. Our initial findings appeared to confirm this and the material fulfilled criteria of validity generally applied when an immunoassay is employed on a new biological matrix, i.e. parallelism and chromatographic identity. Further experiments demonstrated that prolactin concentrations in cervical mucus were less than 40 mUlL and the prolactin-like immunoreactivity originally detected was due to the action of the enzyme bromelin which was used to liquefy the mucus. Bromelin has a similar molecular weight to prolactin and appeared to digest prolactin tracer and reduce its ability to bind antiserum in a manner paralleling the effect of adding pituitary prolactin.
Prolactin has been reported to be present in relatively high concentrations in a number of body fluids including amniotic fluid;' rnilk.i semen" 4 and cervical mucus-where it has been suggested that it may alter the receptivity of the mucus to spermatozoa at mid-cycle by altering the concentration of electrolytes."
Many studies have shown that in plasma, prolactin, as identified by radioimmunoassay, is present in three different molecular forms:": 7 the smallest (mol. wt. 22 0(0) corresponding to monomeric prolactin, and the larger forms (mol. wt. 50 000 and greater than 100 000 daltons) to dimer and aggregate or precursor respectively. Size heterogeneity of immunoreactive prolactin has been reported in amniotic fluid," cerebrospinal fluid" and seminal plasma. III This study was originally undertaken to confirm that prolactin was present in cervical mucus and to investigate whether it was present in different molecular weight forms.
Samples of cervical mucus were obtained from a seminology laboratory attached to an inferility out-patient clinic. These samples had been collected for sperm antibody investigations and had already been treated with bromelin, a peptidase obtained from plants of the pineapple family, 11 in order to liquefy the mucus and make it easier to pipette.
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During the course of the investigation it became apparent that this enzyme was interferring in the radioimmunoassay for prolactin. This paper is a report of this effect.
Materials and methods

SAMPLES
Samples of mucus were collected, during the periovulatory period, from subjects having regular menstrual cycles who were attending an infertility clinic. They were instructed to abstain from sexual intercourse for 3 days prior to collection.
TREATMENT OF SAMPLES
Three methods of pretreatment of samples before assay were investigated. All samples were stored at -20°C after liquefaction.
Bromelin treatment
One vial of bromelin (Blood Transfusion Service, Central Laboratory, Amsterdam, Netherlands) was diluted with 2 mL of 0·88% sodium chloride solution to give a stock solution containing ()·5% bromelin. An equal volume of bromelin solution was added to each sample of cervical mucus and the sample was left to liquefy at ambient temperature.
Freezing and thawing
Samples were mechanically disrupted by slow freezing and thawing. Each sample was put through the freezelthaw cycle 10 times or until liquefaction was achieved. Control experiments were carried out at the same time using a pituitary prolactin standard (WHO Reagent Programme) in phosphate buffer containing 0·1% BSA.
Dilution and homogenisation
Samples of mucus were diluted with an equal volume of 0·1 M phosphate buffer and then homogenised using a glass/teflon Potter Elvejhm homogeniser. RADIOIMMU NOASSA Y Fractions obtained after gel filtration, samples of cervical mucus and bromelin were analysed using well-characterised, widely available reagents and methodologies for the immunoassay of prolactin supplied by the Matched Assay Reagent Programme of the Special Programme for Research in Human Reproduction of the World Health Organisation 12 with the modification of diluting the antiserum (code 82E) to a final dilution of 1 in 3 million. The range covered by the dose-response curve was then 4·9-1250 mUlL with a detection limit of 2·5 mUlL.
GEL FILTRATION
Chromatography of cervical mucus and bromelin solutions was carried out at ambient temperature on a column (0·9X60 cm) containing Ultragel AcA54 (LKB Ltd, London, UK) at a flow rate of 5-8 mL per hour using an eluant buffer of 0·1 M sodium phosphate, pH 7·4, containing 0·1 % wlv bovine serum albumin (Sigma, Poole, UK) and 0·1 % merthiolate (British Drug Houses, Poole, UK). Fractions of 30 drops (approximately 0·75 mL) were collected and duplicate aliquots of 0·2 mL were taken for radioimmunoassay. The column was calibrated using Blue Dextran 20011 (Pharmacia, London, UK) to measure the void volume and with prolactin (WHO International Reference Preparation for Pituitary Prolactin, Code 75/504, National Institute for Biological Standards, London, UK) and serum obtained from late pregnancy.
Results
IMMUNOREACTIVE 'PROLACTIN' IN
BROMELIN-TREATED CERVICAL MUCUS
High levels of prolactin-like immunoreactivity were found in bromelin-treated mucus. Variability between samples was high, and the range of concentrations observed in 52 samples was 450-13 600 mUlL with a mean of 3300 mUlL.
Cervical mucus samples from four subjects with very high levels of immunoreactive prolactin were selected for further analysis. Dilutions of these samples were made with buffer and the resulting six-point dilution curves were compared with standard curves prepared using pituitary prolactin using a four-parameter loglogistic RIA data analysis programme. 13 None of the immunoreactivity observed in the cervical mucus gave dilution curves that were significantly non-parallel (at the 5% level) to the calibration curves obtained using pituitary prolactin (Fig. 1) . Control experiments were performed using four dilutions of each of three different serum pools, no significant nonparallelism between serum and pituitary prolactin was discernible.
Immunoassay of fractions obtained after gel filtration of human serum and of bromelintreated cervical mucus produced the elution patterns shown in Fig. 2a . 'Prolactin' found in bromelin-treated cervical mucus had one single peak, corresponding in position to monomeric prolactin.
PROLACTIN-LIKE IMMUNOREACTIVITY IN
MECHANICALLY DISRUPTED CERVICAL
MUCUS
The concentrations of prolactin-like immunoreactivity in cervical mucus liquefied using physical methods were low: 38±12 mUlL (n=6) in mucus that had been frozen and thawed. Solutions of pituitary prolactin standard which had been frozen and thawed in the same way showed no loss in immunoreactivity. When samples of cervical mucus were diluted with phosphate buffer (0,1 M) as outlined by Sheth et al. 5 the resulting mixture was too viscous for analysis and further homogenisation was found to be necessary in order to liquefy the samples sufficiently for assay. The levels of prolactin-like immunoreactivity measured were then even lower, 9·7±2·2 mUlL (n=4).
ASSAY OF BROMELIN
The dose-response curve of bromelin (doubling dilutions from 0·25% w/v) in the prolactin radioimmunoassay was significantly nonparallel (at the 5% level) with pituitary prolactin ( Fig. 1) . Figure 2b shows the elution profile obtained when bromelin was passed through an Ultragel AcA54 column and the eluate analysed. When the peak fractions were pooled and serial dilutions of bromelin compared with pituitary prolactin, no significant nonparallelism (at the 1% level) was observed between the bromelin and the prolactin standard. The gel-filtration elution pattern obtained when iodinated prolactin was fractionated is shown in Fig. 3a . Three peaks were observed, the first corresponding to an aggregated form of prolactin, the second to monomeric prolactin and the third to free iodide. When prolactin tracer was incubated overnight at 4°C with bromelin (0·25%) prior to gel filtration, protein peaks were reduced in size and the presence of low molecular weight iodinated peptide debris was indicated by the marked 'leading edge' to the iodine peak (Fig. 3b ). When prolactin, bromelin and 1 rnx tosyl-Iysyl chloromethyl ketone (TLCK), a peptidase inhibitor, 14 were incubated under the same conditions prior to gel filtration, the presence of the peptidase inhibitor resulted in an elution profile similar to that obtained with labelled prolactin alone (Fig.  3c ). 
Discussion
Levels of prolactin in untreated or mechanically disrupted cervical mucus were less than 40 mUlL which is approximately 20{) times lower than the levels reported by Sheth et al.,' and the discrepancy between these two studies is difficult to reconcile. It is possible that the antisera used in radioimmunoassays by the two groups had different specificities and were looking at different antigenic determinants. Alternatively, the two assay systems could be affected differently by non-specific factors; for example a dialysable molecule which interferes in prolactin assays is known to be present in urine."
It was not possible to investigate the size heterogeneity of the prolactin-like immunoreactivity that was found in untreated cervical mucus as the concentrations present were low and the fractions obtained after gel filtration were too dilute for analysis.
In the initial stages of this investigation bromelin-treated cervical mucus was used and high levels of prolactin-like immunoreactivity were detected. Classical tests of identity were performed to confirm that the material detected was indeed prolactin. Dilutions of bromelin made from two different matrices (buffer and mucus) produced dose-response curves that were not significantly non-parallel to preparations of pituitary prolactin. even when rigorous statistical checks were applied. Since it is well known that parallelism does not prove that two materials are identical. analysts perform further checks to confirm that an assay is analytically valid. The most common of these is a check of the chromatographic identity of the test and reference compounds. In this instance, bromelin has a molecular weight of 25 000 daltons, which is similar to that of prolactin and it therefore eluted in the same fractions after gel filtration. It was observed that the enzyme appeared to digest iodinated prolactin and a potent inhibitor of trypsin. TLCK, was found to reduce the apparent 'displacement' by bromelin of iodinated prolactin from anti-prolactin serum and also inhibited the hydrolysis of prolactin t~acer. It is interesting to note that the enzymatic hydrolysis of prolactin tracer was doserelated in a way that imitated the effect of adding cold prolactin.
Another group!" has recently reported that glucagon-like immunoreactivity believed to be present in salivary gland extracts was in fact due to the destruction of glucagon tracer by a protease present in the extract.
Such studies underline the continuing need to e~aluate critically the validity of structurally directed assays especially when they are applied to new body fluids.
